Kim Henriksen

Kim Henriksen

Auto-generated profile, based on publicly available information

Kim Henriksen

Nordic Bioscience, Herlev, Denmark

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2006 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
DLDiana Orsnes Leeming
Diana Orsnes Leeming
GDGünTer Delling
GünTer Delling
MKMitsuru Koizumi
Mitsuru Koizumi
KHKim Henriksen
Kim Henriksen
MKMorten Asser Karsdal
Morten Asser Karsdal
IBInger Byrjalsen
Inger Byrjalsen
We recently showed that increased urinary excretion of the cross-linked, nonisomerized form of the C-telopeptide of collagen type I (ααCTX) could be a sensitive indicator of the presence of bone metastases in breast cancer patients. The present study was sought to investigate (a) the localization of αCTX epitopes in the proximity of a bone metastasis and (b) the relationship between number of metastases and the urinary excretion of ααCTX. Adjacent bone sections from breast cancer patients were stained for the presence of tumor cells (anti-cytokeratin antibody), osteoclasts (TRAcP activity), and αCTX (anti-αCTX antibody). The association between the extent of metastatic bone disease and urinary excretion of ααCTX measured with ELISA was assessed in 90 breast cancer patients (45 with bone metastasis and 45 without bone metastasis). Immunohistochemistry revealed accumulation of TRAcP-positive osteoclasts and intense staining for αCTX epitopes in the proximity of cytokeratin-positive bone metastasis. Areas of αCTX staining showed unstructured bone tissue under polarized light. In addition, there was a significant linear association between the number of bone metastases and the urinary levels of ααCTX in breast cancer patients with metastatic bone disease, independent of age and body mass index (r = 0.56, P < 0.001). The estimated relative increases in ααCTX associated with the presence of one, two, or three metastases are 38%, 57%, and 81%, respectively. Taken into account the 17% intraindividual variation of the assay, ααCTX could be a sensitive biochemical marker for the close monitoring of cancer patients aiming the facilitation of early metastasis detection. (Cancer Epidemiol Biomarkers Prev 2006;15(7):1392–5)

28 November 2020 in BMC Musculoskeletal Disorders
Verified
Journal Article
Open access
PDF file
CTChristian S. Thudium
Christian S. Thudium
Signe Holm NielsenSigne Holm Nielsen
Signe Holm Nielsen
SSSamra Sardar
Samra Sardar
Ali MobasheriAli Mobasheri
Ali Mobasheri
ESErwin (W.E.) Van Spil
Erwin (W.E.) Van Spil
MKMorten Asser Karsdal
Morten Asser Karsdal
Osteoarthritis, rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, all have one clear common denominator; an altered turnover of bone. However, this may be more complex than a simple change in bone matrix and mineral turnover. While these diseases share a common tissue axis, their manifestations in the area of pathology are highly diverse, ranging from sclerosis to erosion of bone in different regions. The management of these diseases will benefit from a deeper understanding of the local versus systemic effects, the relation to the equilibrium of the bone balance (i.e., bone formation versus bone resorption), and the physiological and pathophysiological phenotypes of the cells involved (e.g., osteoblasts, osteoclasts, osteocytes and chondrocytes). For example, the process of endochondral bone formation in chondrocytes occurs exists during skeletal development and healthy conditions, but also in pathological conditions. This review focuses on the complex molecular and cellular taxonomy of bone in the context of rheumatological diseases that alter bone matrix composition and maintenance, giving rise to different bone turnover phenotypes, and how biomarkers (biochemical markers) can be applied to potentially describe specific bone phenotypic tissue profiles.

26 August 2014 in Arthritis Care & Research
Verified
Journal Article
Closed access
PDF file
MKMorten Asser Karsdal
Morten Asser Karsdal
AJAnne-Christine Bay Jensen
Anne-Christine Bay Jensen
KHKim Henriksen
Kim Henriksen
CCClaus Christiansen
Claus Christiansen
HGHarry K. Genant
Harry K. Genant
APAdam Platt
Adam Platt

21 May 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
KHKim Henriksen
Kim Henriksen
KBKaren Broekhuizen
Karen Broekhuizen
WBWadim M I de Boon
Wadim M I de Boon
MKMorten A Karsdal
Morten A Karsdal
ABAsger R Bihlet
Asger R Bihlet
IKIngrid Kamerling
Ingrid Kamerling

10 April 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
KHKim Henriksen
Kim Henriksen
MCM. V. Chakravarthy
M. V. Chakravarthy
CBC. L. Bager
C. L. Bager
ALA. T. Larsen
A. T. Larsen
KMK. E. Mohamed
K. E. Mohamed
MKM. A. Karsdal
M. A. Karsdal

1 May 2025 in Journal of Cardiovascular Pharmacology
Verified
Journal Article
Closed access
SJStine Marie Jansen
Stine Marie Jansen
RPRastislav Pitek
Rastislav Pitek
MKMorten Asser Karsdal
Morten Asser Karsdal
KHKim Henriksen
Kim Henriksen
The NC1 domains of collagens have been shown to possess antiangiogenic potential and, therefore, are of therapeutic interest for cancer. However, endostatin and other NC1 domains have not been successful in clinical tests. Therefore, we used evolutionary conservation to perform molecular deconstruction of the domains to further understand their structure–activity relationship, thereby deciphering their antiangiogenic potential. Homology exploration revealed that collagen type X contains a highly interesting NC1 domain (decastatin), with several sequences showing significant homology with vastatin, which is a known collagen type VIII-derived NC1 domain. For comparison, endostatin and vastatin were split into fragments, some of which contained highly conserved regions. The testing of these peptides revealed that the peptides containing conserved regions induced signaling, and fragment four of decastatin showed the highest potency of all fragments, with a calculated IC50 value of 2.7 μM in the human umbilical vein endothelial cell (HUVEC)-based tube formation assay, which is like that of an intact NC1 domain. Notably, the corresponding fragment from vastatin (V4) also inhibited tube formation, suggesting that this region is of therapeutic interest. In summary, we used evolutionary conservation to identify a novel NC1 domain of collagen type X, a collagen playing a role in angiogenesis of the growth plate. Furthermore, we provided data indicating that the antiangiogenic activity of NC1 domain–derived peptides reside within their conserved domains. As a result, we identified a fragment called Decastatin fragment 4 (D4) derived from the NC1 domain of collagen type X, and which has potent antiangiogenic activity.